Glipride MP1 Tablet is a combination oral hypoglycemic agent containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This formulation leverages the complementary mechanisms of its components to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which enhances insulin responsiveness in adipose tissue, muscle, and the liver. The combined effect of these agents addresses multiple pathophysiological defects in type 2 diabetes, including insulin resistance and impaired insulin secretion. Glipride MP1 is prescribed as part of a comprehensive treatment plan that includes diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to any component. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and weight gain. Dose adjustments and monitoring of glycemic status are essential to optimize therapeutic outcomes and minimize risks.